McKesson Co. (NYSE:MCK) Stock Holdings Increased by McBroom & Associates LLC

McBroom & Associates LLC lifted its position in McKesson Co. (NYSE:MCK) by 4.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,816 shares of the company’s stock after acquiring an additional 82 shares during the quarter. McKesson accounts for approximately 0.6% of McBroom & Associates LLC’s holdings, making the stock its 26th largest position. McBroom & Associates LLC’s holdings in McKesson were worth $1,035,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in MCK. Wolff Wiese Magana LLC boosted its holdings in McKesson by 742.9% in the third quarter. Wolff Wiese Magana LLC now owns 59 shares of the company’s stock worth $29,000 after purchasing an additional 52 shares during the period. MidAtlantic Capital Management Inc. bought a new position in shares of McKesson in the 3rd quarter worth about $29,000. RPg Family Wealth Advisory LLC acquired a new position in shares of McKesson in the 3rd quarter valued at about $31,000. Synergy Asset Management LLC bought a new stake in shares of McKesson during the 4th quarter valued at about $32,000. Finally, Crews Bank & Trust acquired a new stake in McKesson during the fourth quarter worth about $33,000. 85.07% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other McKesson news, EVP Leann B. Smith sold 579 shares of the business’s stock in a transaction on Monday, December 9th. The shares were sold at an average price of $602.81, for a total transaction of $349,026.99. Following the sale, the executive vice president now directly owns 1,443 shares of the company’s stock, valued at $869,854.83. The trade was a 28.64 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.11% of the stock is currently owned by insiders.

McKesson Stock Performance

Shares of NYSE MCK opened at $603.33 on Tuesday. McKesson Co. has a 1 year low of $464.42 and a 1 year high of $637.51. The stock has a fifty day moving average price of $588.40 and a two-hundred day moving average price of $562.55. The firm has a market cap of $76.59 billion, a P/E ratio of 27.63, a PEG ratio of 1.30 and a beta of 0.52.

McKesson (NYSE:MCK) last released its earnings results on Wednesday, February 5th. The company reported $8.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $8.60 by ($0.57). McKesson had a negative return on equity of 181.26% and a net margin of 0.82%. On average, research analysts predict that McKesson Co. will post 32.69 earnings per share for the current fiscal year.

McKesson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 1st. Investors of record on Monday, March 3rd will be paid a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a yield of 0.47%. The ex-dividend date of this dividend is Monday, March 3rd. McKesson’s dividend payout ratio is presently 13.00%.

Analyst Ratings Changes

MCK has been the subject of several recent research reports. Citigroup lowered their target price on McKesson from $713.00 to $677.00 and set a “buy” rating for the company in a report on Friday, January 10th. StockNews.com upgraded McKesson from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 6th. Bank of America cut their target price on McKesson from $680.00 to $650.00 and set a “buy” rating on the stock in a research note on Monday, January 6th. Mizuho began coverage on shares of McKesson in a research report on Wednesday, December 4th. They set a “neutral” rating and a $630.00 price target for the company. Finally, Baird R W upgraded shares of McKesson from a “hold” rating to a “strong-buy” rating in a research report on Thursday, November 7th. Two research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $645.79.

McKesson Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.